Agilent Technologies

Agilent BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology

Retrieved on: 
Monday, December 4, 2023
Technology, Medical Devices, Medical Supplies, Genetics, Health Technology, Software, Biotechnology, Health, General Health, Hamamatsu, SCMOS, NYSE, Tissue, Immersion, Agilent Technologies, Marketing, C10, DSD, Atmosphere, Water, BioTek, CMOS, Microscope

Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader .
  • In light microscopy, water immersion technology automatically and consistently places a layer of water between the objective lens and the sample.
  • Spinning disk confocal technology improves microscopic images by blocking out-of-focus light from reaching the image sensor.
  • Additionally, integrating it with the Agilent BioTek BioSpa 8 automated incubator enables efficient multi-plate live-cell analysis.

Agilent Reports Fourth-Quarter Fiscal Year 2023 Financial Results

Retrieved on: 
Monday, November 20, 2023
Technology, Medical Devices, Medical Supplies, Genetics, Health Technology, Software, Biotechnology, Health, General Health, Webcast, NYSE, Diagnosis, PST, DGG, Agilent Technologies, EPS, Conference, GAAP, ACG, Video game, Pharmaceutical industry

“The Agilent team continued its strong execution in Q4 and delivered leveraged earnings in 2023 during a challenging year for the industry,” said President and CEO Mike McMullen.

Key Points: 
  • “The Agilent team continued its strong execution in Q4 and delivered leveraged earnings in 2023 during a challenging year for the industry,” said President and CEO Mike McMullen.
  • The Agilent CrossLab Group (ACG) reported fourth-quarter revenue of $404 million, an increase of 6% reported and 4% core(1) year-over-year.
  • Agilent’s management will present additional details regarding the company’s fourth-quarter 2023 financial results on a conference call with investors today at 1:30 p.m. PST.
  • To listen to the webcast, select the “Q4 2023 Agilent Technologies Inc. Earnings Conference Call” link on the Agilent Investor Relations website .

Agilent to Present at the Evercore ISI HealthCONx Conference

Retrieved on: 
Friday, November 17, 2023
Software, Biotechnology, Medical Supplies, General Health, Health, Medical Devices, Health Technology, Technology, Agilent Technologies, NYSE, Management

Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI HealthCONx conference on Wednesday, Nov. 29, at 10:50 a.m. ET.

Key Points: 

Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI HealthCONx conference on Wednesday, Nov. 29, at 10:50 a.m. ET.

Metabolism Assays Research Report 2023: Market Analysis by Instruments, Assays Kits, Colorimetry, Fluorimetry, Spectrometry, Diagnostics, Research - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Biotechnology, Pharmaceutical, Health, Agilent Technologies, Abcam, Investment, Hospital, USD, Compound annual growth rate, Diabetes, Drug discovery, Diagnosis, Growth, Region, Colorimetry, ChromeOS, Merck Group, Thermo Fisher Scientific, Research report, Medical device, Fine chemical, Obesity, Spectrometry, Research

The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%

Key Points: 
  • The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%
    This research report categorizes the Metabolism Assays Market by product, technology, application, end-user, and region.
  • Nevertheless, concerns related to the high cost of metabolism assays act as a hindrance to market growth.
  • Moreover, the region benefits from a growing population afflicted with target diseases, further supporting the expansion of the metabolism assays market.
  • Additionally, the report covers aspects such as new product and service launches, mergers and acquisitions, and recent developments within the metabolism assays market.

Liquid Handling Technologies and Global Markets Report 2023: Revenue Data for 2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Technology, Other Technology, Mettler Toledo, Thermo Fisher Scientific, Research, Acquisition, Investment, Risk, Biotechnology, COVID-19, Automation, Drug discovery, Growth, Agilent Technologies, SE, ESG, Fine chemical, Pharmaceutical industry

The "Liquid Handling: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liquid Handling: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report will focus on liquid handling equipment for biological and chemical laboratory use and applications of the equipment.
  • The global market for liquid handling was valued at $4.2 billion in 2022.
  • This growth is driven by increased awareness of the importance of liquid handling and substantial investments in research and development focused on liquid handling for drug discovery and development.

Agilent Increases Cash Dividend to 23.6 Cents per Share

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Other Health, Health, Technology, Software, Agilent Technologies, NYSE, Holding company

Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend.
  • The quarterly dividend will be paid on Jan. 24, 2024, to all shareholders of record as of the close of business on Jan. 2, 2024.
  • The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, FDA, Medical Devices, Health, Oncology, MSD, HNSCC, PD-L1, Trastuzumab, NYSE, Cervical cancer, Head, Incidence, Patient, Triple-negative breast cancer, Agilent Technologies, Stomach cancer, Stomach, Pembrolizumab, Lung cancer, PD-1, Adenocarcinoma, Partnership, ESCC, Cancer, Merck & Co., Physician, CPS, GEJ, TNBC, NSCLC, Pharmaceutical industry, Vaccine, Merck

Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
  • PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic that can identify gastric or GEJ adenocarcinoma patients suitable for treatment with KEYTRUDA in combination with chemotherapy and trastuzumab plus fluoropyrimidine.
  • This marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval.
  • PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck (known as MSD outside the United States and Canada) as a companion diagnostic for KEYTRUDA.

Agilent Announces Thought Leader Award to Professor Jennifer Field

Retrieved on: 
Monday, November 13, 2023
Software, Research, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, Technology, Science, Telecommunications, Other Science, External, Associate, NYSE, Groundwater, PFAS, Risk, Agilent Technologies, Oregon State University, Health, Agricultural science, Biophysical environment, Fluorine, Management, Environmental remediation

Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award.
  • Professor Field commented on the Agilent Thought Leader Award.
  • Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry division, remarked on the significance of recognizing Professor Field with this award.
  • For more information, please visit the Agilent Thought Leader Award website.

BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual Meeting

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, MSI, WES, TMB, American Securities, Salt Palace, Sequence, Epigenome-wide association study, Molecular diagnostics, Agilent Technologies, Journal, HRD, Chromosomal translocation, R, Molecular reference standards, AMP, Abstract (summary)

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.
  • During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.
  • Details of BostonGene’s presence at AMP are below:
    Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene
    Tumor molecular characterization is key for advancing precision oncology.
  • In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses.

First Tech Federal Credit Union Finds People in Tech Carry 45% Less Credit Card Debt than Members in Other Industries

Retrieved on: 
Wednesday, December 13, 2023
Negotiation, SAN, HP Inc., Nike, Agilent Technologies, Cisco, Intel, Thumb, Housing, Microsoft, Cryptocurrency, Bank, Amazon, Intuit

SAN JOSE, Calif. and HILLSBORO, Ore., Dec. 13, 2023 /PRNewswire-PRWeb/ -- This year, technology layoffs have surged past 240,000 globally, a 50% increase from 2022, but new data suggests people working in tech are managing finances more effectively, according to First Tech Federal Credit Union, the banking partner for tech innovators. The new insights are based on an analysis of First Tech's nearly 700,000 members, including many people working in the tech industry. The data shows tech-based members have 45% less in credit card debt than their non-tech counterparts - and while credit card balances for non-tech members are up 25% year-over-year, tech-based members only saw a 4% increase in credit card balances during the same period.

Key Points: 
  • The new insights are based on an analysis of First Tech's nearly 700,000 members, including many people working in the tech industry.
  • The data shows tech-based members have 45% less in credit card debt than their non-tech counterparts - and while credit card balances for non-tech members are up 25% year-over-year, tech-based members only saw a 4% increase in credit card balances during the same period.
  • The data shows tech-based members have 45% less in credit card debt than their non-tech counterparts - and while credit card balances for non-tech members are up 25% year-over-year, tech-based members only saw a 4% increase in credit card balances during the same period.
  • However, tech members show healthier balances, with 167% more in their checking accounts than non-tech members, with an average balance of over $16,548.